Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Study of Hexaxim Compared With Pentaxim Administered With a Monovalent Hepatitis B Vaccine in Healthy Chinese Infants.

10 novembre 2026 aggiornato da: Sanofi

A Nested Phase 3, Randomized, Active-controlled, Open-label, 2-arm, Multicenter Study to Investigate the Immunogenicity and Safety of Sanofi's Hexavalent DTaP-IPV-HB-PRP~T Combined Vaccine Given at 2, 4, and 6 Months of Age Compared With DTaP-IPV//PRP~T Combined Vaccine (Pentaxim™) Given at 2, 4, and 6 Months of Age Administered With a Monovalent Hepatitis B Vaccine Given at 1 and 6 Months of Age to Healthy Chinese Infants Who Previously Received a Birth Dose of Monovalent Hepatitis B Vaccine

The purpose of this study is to measure the safety and immunogenicity of Hexaxim given at 2, 4, and 6 MoA compared with Pentaxim given at 2, 4, and 6 MoA plus a monovalent Hep B vaccine given at 1 and 6 MoA in healthy Chinese infants born to HBsAg seronegative mothers.

Study details include:

  • The study duration per participant will be approximately 18 months.
  • The study vaccines administration:
  • Group 1: for the primary series vaccination, Hexaxim will be administered 3 doses at 2, 4, and 6 MoA.
  • Group 2: for the primary series vaccination, Pentaxim will be administered 3 doses at 2, 4, and 6 MoA, and the monovalent Hep B vaccine will be administered at 1 and 6 MoA.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

720

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Trial Transparency email recommended (Toll free for US & Canada)
  • Numero di telefono: option 6 800-633-1610
  • Email: Contact-US@sanofi.com

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 1 mese a 1 mese (Bambino)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Aged 30 to 45 days on the day of inclusion, and have received 1 dose of monovalent Hep B vaccine
  • Born at full term of pregnancy (≥37 weeks) and with a birth weight ≥2.5 kg or born after a gestation period above 28 (>28 weeks) through 36 weeks with a birth weight ≥1.5 kg, and in both cases medically stable as assessed by the investigator
  • Participants who are born to mothers with documented HBsAg seronegative status
  • Informed consent form has been signed and dated by the parent(s) or other LAR
  • Participant and parent/LAR are able to attend all scheduled visits and to comply with all study procedures

Exclusion Criteria:

  • Known/suspected immunodeficiency; immunosuppressive therapy since birth; long-term systemic corticosteroid therapy
  • History of diagnosis of Hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b infection
  • History of seizure or significant stable or progressive neurological disorders
  • Known systemic hypersensitivity to any study intervention components, or history of a life-threatening reaction to study interventions or product with the same substances
  • Known thrombocytopenia
  • Bleeding disorder
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • Moderate or severe acute illness/infection (according to investigator judgment) or febrile illness (axillary temperature ≥37.5°C) on the day of study intervention administration. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Any vaccine given since birth or planned receipt of any vaccine until 1 month after the completion of the primary series vaccination with the study interventions except for Bacille Calmette-Guérin (BCG) vaccine and meningococcal polysaccharide vaccine-A.
  • Previous vaccination against D, T, pertussis, poliomyelitis, Hep B (except the dose of Hep B given at birth) or Haemophilus influenzae type b infections (since birth) with an investigational or marketed vaccine.
  • Receipt of immune globulins, blood or blood-derived products
  • Participation in another clinical study for a vaccine, drug, medical device, or medical procedure at the time of study enrollment or planned participation during the present study period.
  • Known personal or maternal history of HIV or HCV seropositivity
  • Being in an emergency setting
  • Identified as a natural or adopted child of the Investigator/study site employee with direct involvement in the study

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group 1 (the investigational group)

Hexaxim at 2, 4 and 6 MoA

Pharmaceutical form:Suspension for injection in a pre-filled syringe Route of administration:IM injection

Comparatore attivo: Group 2 (the comparator group)

Pentaxim at 2, 4, 6, and 18 MoA, and the monovalent Hepatitis B vaccine at 1 and 6 MoA

Pharmaceutical form:Freeze-dried PRP~T in a vial reconstituted with the injectable suspension of DTaP-IPV in a pre-filled syringe Route of administration:IM injection

Pharmaceutical form: Depending on the brand procured Route of administration:IM injection

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
1 month after the last dose of primary series (investigational group [Hexaxim: Group 1] and comparator group [Pentaxim and monovalent Hep B: Group 2]) (7 MoA):
Lasso di tempo: Day181

Anti-D Ab concentrations ≥0.1 IU/mL Anti-T Ab concentrations ≥0.1 IU/mL Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Anti-PRP Ab concentrations ≥0.15 µg/mL Seroconversion for anti-PT and anti-FHA, defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Dose 1 to 1 month post-Dose 3 Anti-Hep B Ab concentrations ≥10 mIU/mL GMC of PT and FHA

Day181

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Baseline, pre-vaccination sample
Lasso di tempo: Day 31

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL and ≥0.1 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL
  • Anti-Hep B Ab concentrations ≥10 mIU/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
Day 31
1 month after the last dose of primary series:
Lasso di tempo: Day181

Ab concentrations/titers for each Ag

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 μg/mL and ≥1.0 μg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL Ab individual concentration/titer ratios for all antigens except for Hep B) (post-Dose 3/pre-Dose 1) Anti-Hep B Ab individual concentration ratio (post-Dose 4 Hep B/pre-Dose 2 Hep B in the investigational group, or post-Dose 3 Hep B/post-Dose 2 Hep B in the comparator group) Note: Dose 1 Hep B corresponds to the dose of Hep B vaccine given at birth.
Day181
Before the booster dose:
Lasso di tempo: Day 511

Ab concentrations/titers for each

Ag of Pentaxim and Hep B Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil)
  • Anti-Hep B Ab concentrations ≥10 mIU/mL and ≥100 mIU/mL
Day 511
1 month after the booster dose:
Lasso di tempo: Day 541

Ab concentrations/titers for each Ag of Pentaxim

Ab concentrations/titers above a cut-off:

  • Anti-D Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-T Ab concentrations ≥0.01 IU/mL, ≥0.1 IU/mL, and ≥1.0 IU/mL
  • Anti-PRP Ab concentrations ≥0.15 mg/mL and ≥1.0 mg/mL
  • Anti-polio 1, 2, and 3 Ab titers ≥8 (1/dil) Seroconversion for anti-PT and anti-FHA defined as anti-PT and anti-FHA ≥4-fold Ab concentrations increase from pre-Booster to post-Booster Ab individual concentration/titer ratios for all antigens (post-Booster/pre-Booster)
Day 541
Presence of immediate unsolicited adverse events (AEs)
Lasso di tempo: 30 minutes after each and any vaccination
30 minutes after each and any vaccination
Presence of solicited injection site reactions
Lasso di tempo: for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and case report form [CRF])

for 8 days, including the day of each and any vaccination
Presence of solicited systemic reactions
Lasso di tempo: for 8 days, including the day of each and any vaccination

(pre-listed in the participant diary and CRF)

for 8 days, including the day of each and any vaccination
Presence of unsolicited AEs
Lasso di tempo: for 30 days, including the day of each and any vaccination
for 30 days, including the day of each and any vaccination
Presence of serious adverse events (SAEs)
Lasso di tempo: up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
up to 12 months post last dose of vaccination in the primary series, and up to 1 month post booster vaccination
Presence of related SAEs and fatal case regardless of causality
Lasso di tempo: Day 541
Day 541
Presence of AEs leading to study discontinuation
Lasso di tempo: Day 541
Day 541

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

28 dicembre 2026

Completamento primario (Stimato)

27 aprile 2028

Completamento dello studio (Stimato)

30 luglio 2029

Date di iscrizione allo studio

Primo inviato

10 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

10 novembre 2026

Primo Inserito (Effettivo)

17 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • A3L00054
  • U1111-1227-3420 (Identificatore di registro: ICTRP)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi